As the Hippo pathway is known to be a regulator of cancer stem cells [18, 31–33] and is involved in cell adhesion and migration, which are closely associated with cancer progression and metastasis [34–36], our results suggest that ERK1/2 should be a therapeutic target in this process. This evidence concerns the gene MAPK3 and cancer.